comparemela.com

Latest Breaking News On - Renalys pharma - Page 1 : comparemela.com

Travere Therapeutics Reports First Quarter 2024 Financial Results

FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511.

Japan
United-states
Norway
Iceland
Liechtenstein
Japanese
American
Renalys-pharma
Deric-dube
Drug-administration
Program-updates
National-symposium

Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan

Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Laos
Brunei
Singapore
Chuo-ku
Tokyo
Japan
Taiwan
Malaysia
Thailand
Indonesia
Vietnam
Republic-of

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval .

Liechtenstein
Iceland
Japan
Norway
Deric-dube
Drug-administration
European-union
Devices-agency
Program-updates
Committee-for-medicinal-products-human-use
Nasdaq
Renalys-pharma-inc

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.

Vietnam
Republic-of
Taiwan
Malaysia
Thailand
Indonesia
Singapore
Philippines
Laos
Brunei
Cambodia
South-korea

vimarsana © 2020. All Rights Reserved.